Medicine-delivery player PharmEasy, which was grappling with a debt pile and some weakness in business, has received a timely boost. Existing investors have oversubscribed its right issue of Rs 3,500 crore ($420 million). Additionally, the company recorded an EBITDA of Rs 60 crore ($7.2 million) in the six-month period from April to September 2023.